Latest Avecho Biotechnology (ASX:AVE) News

Avecho Biotechnology has inked a decade-long exclusive licensing agreement with Sandoz for its pharmaceutical-grade cannabidiol capsule targeting insomnia in Australia, backed by a US$3 million upfront payment and promising milestone and royalty streams.

Avecho Biotechnology has responded to an ASX price query, confirming no undisclosed information exists to explain recent trading spikes, while highlighting market speculation linked to its Phase III CBD insomnia trial.

Avecho Biotechnology progresses its Phase III clinical trial for a TPM®-enhanced CBD insomnia capsule, expands patient recruitment, and completes a major manufacturing campaign for its U.S. partner Ashland.